课题基金 / 基金详情

项目摘要

项目成果

ELISABETH M ALICOT-CARROLL的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):美国每年有100多万人患有急性心肌梗死(AMI),目前除了直接经皮冠状动脉介入治疗外,没有其他预防性治疗方法。DecImmune的长期目标是开发治疗方法,以减少冠状动脉阻塞解除后的严重致命性再灌注损伤。这一目标是基于我们确定了一种新的途径,该途径通过缺血组织的再灌注和多肽模拟表位(N2)和阻断炎症的单抗的开发而激活。目前的提议是重新提交一项申请,该申请是在我们完成较早的第一阶段赠款的里程碑之后提出的。经修订的申请解决了审查员的关切,并包括大量新成果,如更详细和完整的议定书和增加生猪数量以加强统计能力。我们早期的研究表明,我们在啮齿动物中发现的新途径在人类中是保守的。因此,为了将潜在的治疗方法转移到临床试验,我们建议在猪模型中扩大我们的观察范围。鉴于猪与人类血管系统在生理上高度相似,猪是一个很好的动物模型。成功实现第二阶段应用的目标将导致在第一阶段临床试验中对这些疗法进行测试。 与公共健康相关:美国每年有超过120万例心脏病发作。尽管在溶栓治疗和血管成形术方面取得了进展,但多达25%的男性和38%的女性在心脏病发作后一年内死亡。高发病率和高死亡率的一个重要因素是由于缺血和再灌流部位的急性炎症对心脏组织造成的损害。该项目的目标是开发一种治疗化合物,它将抑制心肌梗死后患者缺血部位发生的急性炎症,将微血管损伤量降至最低,并保护梗死区存活的心肌细胞。申请书中描述的研究将把我们对抑制剂的测试扩展到猪的急性心肌梗死模型。
英文摘要
DESCRIPTION (provided by applicant): Acute myocardial infarction (AMI) affects over 1 million US individuals a year and at present there are no preventative therapeutics other than direct percutaneous coronary intervention. DecImmune's long-term goal is to develop therapeutics to reduce the severe lethal reperfusion injury that follows removal of coronary artery blockage. This goal is based on our identification of a novel pathway that is activated by reperfusion of ischemic tissues and development of a peptide mimetope (N2) and monoclonal antibodies that block inflammation. The current proposal is a resubmission of an application that follows from our completion of the milestones of an earlier Phase I grant. The revised application addresses the concerns of the reviewers and includes substantial new results such as a more detailed and complete protocol and an increased number of pigs to enhance statistical power. Our earlier studies demonstrated that the novel pathway we identified in rodents is conserved in humans. Therefore, in order to move the potential therapeutics to clinical trials, we propose to extend our observations in a pig model. Given the high degree of physiological similarities with the human vascular system, pigs represent a good animal model. Successful achievement of the goals of the Phase II application will lead to testing of the therapeutics in Phase I clinical trials. PUBLIC HEALTH RELEVANCE: There are over 1.2 million heart attacks annually in the US. In spite of advances made in thrombolytic therapy and angioplasty, up to 25% of men and 38% of women die within one year following a heart attack. A significant factor in the high morbidity and mortality is due to the damage that is caused to the cardiac tissues by acute inflammation at the site of ischemia and reperfusion. The goal of this project is to develop a therapeutic compound that will inhibit the acute inflammation that occurs at the site of ischemia in patients following a myocardial infarction, minimizing the amount of microvascular damage and protecting viable cardiac cells in the infarct zone. Studies described in the application will extend our testing of the inhibitors to a swine model of acute myocardial infarction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic to Reduce Acute Inflammation in Severe Burn Injuries
  • 批准号:
    7053478
  • 项目类别:
  • 资助金额:
    $12.92万
  • 财政年份:
    2006
  • 负责人:
    ELISABETH M ALICOT-CARROLL
  • 依托单位:
Therapeutic to Reduce Acute Inflammation Following Cardiac Ischemia
  • 批准号:
    7909256
  • 项目类别:
  • 资助金额:
    $111.91万
  • 财政年份:
    2006
  • 负责人:
    ELISABETH M ALICOT-CARROLL
  • 依托单位:
Therapeutic to Reduce Acute Inflammation Following Cardiac Ischemia
  • 批准号:
    7109773
  • 项目类别:
  • 资助金额:
    $12.92万
  • 财政年份:
    2006
  • 负责人:
    ELISABETH M ALICOT-CARROLL
  • 依托单位:
海外基金